Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Solanezumab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Solanezumab (Anti-Amyloid Beta)

Synonyms: Abeta， A4

Solanezumab (Anti-Amyloid Beta) is a humanized monoclonal IgG1 antibody targeting the mid-domain of the amyloid-β (Aβ) peptide. It has the potential for the research of Alzheimer’s disease. MW :144.34 KD.

Solanezumab (Anti-Amyloid Beta)

Quality Control

Batch: A306401 Purity: 99% Protein concentration: 4.15mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Solanezumab (Anti-Amyloid Beta) is a humanized monoclonal IgG1 antibody targeting the mid-domain of the amyloid-β (Aβ) peptide. It has the potential for the research of Alzheimer’s disease. MW :144.34 KD.
References

Product Details

CAS No. 955085-14-0
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01760005 ACTIVE_NOT_RECRUITING Drug: Gantenerumab|Drug: Solanezumab|Drug: Matching Placebo Alzheimers Disease; Dementia; Alzheimers Disease, Familial Washington University School of Medicine 2012-12 PHASE2; PHASE3
NCT02008357 COMPLETED Drug: Placebo|Drug: Solanezumab Cognition Disorders Eli Lilly and Company 2014-02-28 PHASE3
NCT04623242 COMPLETED Drug: Gantenerumab|Drug: Solanezumab|Drug: Matching Placebo Alzheimers Disease; Dementia; Alzheimers Disease, Familial Washington University School of Medicine 2012-12 PHASE2; PHASE3
NCT02760602 TERMINATED Drug: Solanezumab|Drug: Placebo Alzheimer's Disease Eli Lilly and Company 2016-06 PHASE3
NCT02614131 TERMINATED Drug: LY2599666|Drug: Solanezumab|Drug: Placebo SC|Drug: Pla Healthy; Alzheimer's Disease; Mild Cognitive Impairment Eli Lilly and Company 2015-12 PHASE1
NCT01900665 TERMINATED Drug: Solanezumab|Drug: Placebo Alzheimer's Disease Eli Lilly and Company 2013-07 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.